Is B-cell depletion still a good strategy for treating immune thrombocytopenia?

Abstract

B cells play an important role in the pathophysiology of immune thrombocytopenia (ITP). Thus, a rational approach to ITP treatment involves B-cell depletion such as with rituximab. More than 10 years after the first reports of data suggesting that anti-CD20 MoAbs could be effective treatment for ITP, we have now a clear view of its efficacy, with an overall… (More)
DOI: 10.1016/j.lpm.2014.01.011

Topics

Cite this paper

@article{Godeau2014IsBD, title={Is B-cell depletion still a good strategy for treating immune thrombocytopenia?}, author={Bertrand Godeau and Roberto Stasi}, journal={Presse medicale}, year={2014}, volume={43 4 Pt 2}, pages={e79-85} }